Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review
Jenkins, Abi;(BSAC Working Party on Therapeutic Drug Monitoring);Thomson, Alison H.;(BSAC Working Party on Therapeutic Drug Monitoring);Brown, Nicholas M.;(BSAC Working Party on Therapeutic Drug Monitoring);Semple, Yvonne;(BSAC Working Party on Therapeutic Drug Monitoring);Sluman, Christine;(BSAC Working Party on Therapeutic Drug Monitoring);MacGowan, Alasdair;(BSAC Working Party on Therapeutic Drug Monitoring);Lovering, Andrew M.;(BSAC Working Party on Therapeutic Drug Monitoring);Wiffen, Phil J.;(BSAC Working Party on Therapeutic Drug Monitoring);
journal of antimicrobial chemotherapy2016Vol. 71pp. 2754-2759
184
abi2016journalamikacin
Abstract
Despite a comprehensive search of the literature, the authors failed to find sufficient evidence for providing guidelines on amikacin dosing and therapeutic dru